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Conclusions: The replication activity of hepatitis B virus in
HBeAg-positive group was higher than another two groups.
The virus replicated actively and liver function damage
by no means synchronization occurrence. Total HBVDNA
in serum samples combined with intrahepatic cccDNA can
better monitor the anti-viral therapy effect and prognosis.
Abbreviation: Alanine aminotransferase (ALT), total
bilirubin (TBIL), hepatitis B e antigen (HBeAg)
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inhibiting B and C genotype HBV in vitro
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Until recently, only alpha interferon and nucleotides
(analogue) were available for the treatment of HBV.
However, the low efﬁcacy, undesirable side-effects, and
drug- resistance remain the major obstacles in treating HBV
infection, the need for alternative therapeutic measures has
provided the impetus to develop novel therapeutic reagents
for inhibiting HBV replication.
RNAi has proven to be very powerful in inhibiting HBV
replication by cell culture and mouse model studies. The
present study all designed perfect match siRNAs to target
HBV, as we all known that HBV exist as quasispecies, so, it
is essential to study inhibitory effect of mismatched siRNAs
on target HBV; here, we study the inhibitory effect of 2 4
bases mismatch shRNAs on HBV.
Objective: To assess the inhibitory effect of shRNAs with
mismatching with target sequence on B and C genotype
HBV.
Methods: shRNA and pHY106-BHBV or pHY106-CHBV
cotransfected HepG2 cells, the supernatant of the culture
at 24 h, 48 h, 72 h, 96 h and 120 h after cotransfection
was collected and frozen in 20ºC for examining HBsAg
and HBeAg by ELISA; 72 h after cotransfection, the total
RNA of cells was exstracted and reverse-transcripted, then
detecting the level of HBsAg mRNA by RT-PCR; 72 h
after cotransfection, cells were lysated, HBV replicative
intermediate from HBV core particles was exstracted for
southern blot.
Results 1. HBsAg and HBeAg expression were inhibited
obviously by shRNA458 and shRNA635, the inhibitory effect
was detectable at 48 h after cotransfection, the peak time
was 72 h, the most inhibitory ratio was approximately 80%
and 50% in HBsAg and HBeAg; there was no difference
was observed about the the inhibitory action of shRNA458
and shRNA635 on B or C genotype HBV; 2. shRNA458
and shRNA635 had the similar inhibitory action on the
production of HBsAg mRNA in B and C genotype HBV at
72 h after cotransfection, the inhibitory ratio was 60 70%;
3. HBV replicative intermediate from B and C genotype HBV
was inhibited obviously by the two shRNAs also.
Conclusions shRNA458 and shRNA635 have powerfully
inhibitory effect on the expression of HBsAg and HBeAg,
HBsAg mRNA and HBV replication although 2 4 bases
mismatch between shRNAs and target HBV, so shRNA458
and shRNA635 are two powerful tools for inhibiting HBV.
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Background and Aim: The protein-x of Hepatitis B virus
(HBx) interacted directly or indirectly with host factors
to modulate cell signaling pathways and would have
suggested being oncogenic. Though many functions have
been associated with protein-x, the nature of this protein
is not well disclosed. Full understanding of the biological
role of this protein will require a complete knowledge of
its structure. Here we present a structural model to picture
the structure of HBx using computational approaches along
with the available experimental data.
Methods: Protein-x was translated based on its genome
which we have sequenced previously. Bioinformatics tools
were employed for searching Hidden Markov Model and
conserved motif(s). SSpro program was performed to
determine the secondary structure of the protein and the
ProtScale program was used to provide several predeﬁned
amino acid scales. Our model was constructed using 1jfua as
a template by LOMETS server. Optimization of the model was
carried out by the molecular dynamics simulated method.
Results: Analysis of the amino acid sequences of HBx by
pfam database clariﬁed a large conserved domain and motif
search showed a Trans-activation region for protein-x. PSI-
Blast revealed not more than 26% identity against the PDB
database.
Reﬁned model included a stable folding with a coiled
motif and three helical domains with two antiparallel
b-sheets. The model was tested using molecular dynamics
simulation.
Conclusion: Although there is limited knowledge about
protein-x of hepatitis B virus, here we modeled a unique
3D structure for the ﬁrst time. The model was tested for
validation and dynamic simulations in water. This model can
lead to better understanding of the function of protein-x
and its interaction with the cellular proteins that could be
useful for the design of selective inhibitors as a target in
treatment.
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Hepatitis B virus (HBV), the type member of the
Hepadnaviridae, is responsible for infections that cause
B-type hepatitis. The small enveloped HBV virus replicates
via reverse transcription of an intermediate RNA-the
pregenomic RNA (pgRNA), and initiates by protein-priming
to the epsilon (e) stem-loop on the pgRNA. The e hairpin
consists of a lower stem, an apical loop, an upper stem,
and a bulge region which serves as template of priming,
i.e. 3 or 4 nt de novo DNA synthesis. e is essential for
the encapsidation of the pgRNA and initiation of reverse
transcription. Both events are mediated by binding of
reverse transcriptase (P protein) plus cellular chaperones
to e RNA. However, within e, little information is known
which structural elements are indispensable for priming.
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Previously, we have established one e library by introducing
8 randomized sequences in upper stem and selected out a
series of RNA aptamers with higher afﬁnity to P protein
based on the in vitro SELEX in duck hepatitis B virus
(DHBV) system. Interestingly, we observed that only part of
these stronger binders support priming. In order to explore
structural determinants within e, all selected aptamers
were subjected to RNA structural mapping. We found that
an undamaged bulge is essential for initiating priming.
On the other hand, our study demonstrates that the
stronger binders with damaged bulge structure are able
to be potentially used as decoys for antiviral therapy by
interfering with the protein-priming process of wild type
DHBV. The given data also enable us to understand P-e
interactions during HBV replication in details.
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One of the important factors in safety of blood transfusion
is to use an additional sensitive screening test to identify
blood-born infective agents (like HBV). Although HBsAg
screening reduces the risk of HBV transmission, but HBsAg
negative blood donors may yet transmit HBV infection. The
aim of this study was to assess the possibility of using anti-
HBc as a screening test to improve the detection rate of
HBV infection in donated blood in city of Rasht, North of
Iran.
A total of 2,041 blood samples with negative result for
HBsAg, Anti-HCV, Anti-HIV I, II and RPR were collected
and used to detect anti-HBc Ab. If the result of anti-
HBc was positive, the samples were evaluated for HBVDNA
detection. DNA extraction was done by using a commercial
DNA extraction kit (Qiagen) and analyzed using a commercial
quantitative real-time PCR kit (artus HBV LC PCR Kit). The
positive sample was rechecked with a reliable and sensitive
homemade PCR kit.
The prevalence of anti-HBc Ab positive was 78/2041
(0.038%) by total anti-HBc Ab kit. One out of 78 anti-HBc Ab
positive sample was positive for HBVDNA when was checked
by real-time PCR and re-checked by homemade kit.
This study showed that the anti-HBc Ab positivity is lower
than many parts of Iran in Rasht. As anti-HBc Ab positive
blood donors may be a potential source of HBV transmission
further study for evaluation of HBVDNA in anti-HBc positive
blood units is strongly recommended.
PP-013 New perspectives in immunotherapy of
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Background and Aims: The experimentation of antivirals,
new vaccine formulations and adjuvanted antigens, able to
elicit a speciﬁcally targeted cellular response or to interfere
with viral replication to break tolerance, is crucial for
immunotherapeutic approaches of Hepatitis B Virus (HBV)
infection. In this study we have applied the well recognized
preclinical model of the HBV, the Woodchuck (Marmota
monax) chronically infected from Woodchuck Hepatitis Virus
(WHV) with the aim to investigate the neutralization and
antiviral effects of Immune Genic Complex (IGC) composed
by preS/S antibodies and WHV particles in healthy and in
WHV chronically infected animals.
Methods: The characterized and quantiﬁed neutralization
mixture or IGC, was intravenously and intradermically
administered to four WHV negative and ﬁve WHV chronic
carriers. One animal was used as infection control.
Electro-chemi-luminescence immuno-assay (Elecsys, Roche
Molecular Diagnostics) to detect antibody to WHV core
antigen (WHcAb) and WHV “e” antigen (WHeAb), and
WHV “e” antigen (WHeAg) was used. WHV Real-Time PCR
was applied to determine the viral load every two weeks
after IGC administrations and PBMc proliferation assays was
performed making use of Core and PreS/S HBV regions
epitopes.
Results: The IGC administration obtained with the lowest
preS/S antibody amount (2.5mIU) showed, in WHV negative
woodchucks, better neutralization effects in terms of
WHeAg and viral load concentrations in all treated animals
in respect to the controls. The IGC administration in WHV
chronic carriers induced strong antiviral effect in three
out of ﬁve animals. The viral phylogenetic analysis (MEGA 4
program) of PreS/S region showed, in one animal, signiﬁcant
variation during follow up.
Conclusions: This newly designed experimental protocol
will be at the basis for further developments in the ﬁeld
of improvement of antigenic adjuvancy and of therapeutic
vaccines formulations.
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Background and Aims: In treatment of naive chronic
hepatitis B (CHB) patients, Entecavir shows good long term
viral suppression and low rate of development of resistance.
Its role in patients of CHB, who are exposed to lamivudine
therapy, is not clear. We studied the efﬁcacy of Entecavir
in this group of patients.
Methods: Ten patients who showed breakthrough
during lamivudine therapy, were treated with Entecavir
(1mg/day). The dose was modiﬁed in patients of renal
failure as required. HBVDNA quantitative levels were
done 3 monthly to assess adequacy and duration of viral
suppression. Assessment for Entecavir resistance deﬁned as
decline of <1 log10 copies/ml in 12 weeks or increase in
HBVDNA by 1 or 2 log levels were the primary end points.
Results: Of 10 patients (8 male; 8 HBeAg positive,
5 with compensated Liver Cirrhosis) who received Entecavir,
phenotypic resistance to Entecavir was seen in 5 (50%) over
a mean period of 12± 4.58 months. Of these 5, 4 were
